Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia
- PMID: 28445830
- DOI: 10.1016/j.biopha.2017.04.076
Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia
Abstract
Neoplasm cells from patients with chronic myeloid leukemia (CML) interact with stromal cells of the surrounding microenvironment. Bone marrow stromal cells (BMSCs) represent the main population in CML marrow stroma, which may play a key role in disease support and progression. Heme oxygenase-1 (HO-1) is a key enzyme of antioxidative metabolism that is associated with cell proliferation and resistance to apoptosis. We herein up-regulated HO-1 expression of BMSCs and evaluated whether BMSCs influenced K562 cells survival. BMSCs were isolated from the bone marrow of normal people and CML patients. Following co-culture of BMSCs and K562 cells, up-regulating HO-1 expression in bone marrow stromal cells increased the imatinib (IM) resistance of K562 cells, whereas the apoptosis of K562 cells was effectively promoted without BMSCs co-culture. The protection may be mediated by CXCL12 (stromal derived factors 1, SDF-1)/CXCR4 signaling. The CXCL12/CXCR4 interaction significantly enhanced the phosphorylation of AKT. As far as drug resistance was concerned, BMSCs counteracted the cytotoxic effect of IM administration in vitro, and they protected K562 cells from the apoptosis induced by kinase inhibitor IM. The regulated HO-1 expression of BMSCs provides a new putative target for CML therapy.
Keywords: Chronic myeloid leukemia; Heme oxygenase-1; Imatinib; Microenvironment; Resistance.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.Mol Cancer Ther. 2014 May;13(5):1155-69. doi: 10.1158/1535-7163.MCT-13-0410. Epub 2014 Feb 6. Mol Cancer Ther. 2014. PMID: 24502926
-
Heme oxygenase-1 contributes to imatinib resistance by promoting autophagy in chronic myeloid leukemia through disrupting the mTOR signaling pathway.Biomed Pharmacother. 2016 Mar;78:30-38. doi: 10.1016/j.biopha.2015.12.029. Epub 2016 Jan 11. Biomed Pharmacother. 2016. PMID: 26898422
-
Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.Mol Carcinog. 2017 Mar;56(3):863-876. doi: 10.1002/mc.22540. Epub 2016 Sep 22. Mol Carcinog. 2017. PMID: 27533597
-
Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia.Eur J Med Chem. 2017 Dec 15;142:163-178. doi: 10.1016/j.ejmech.2017.07.031. Epub 2017 Jul 20. Eur J Med Chem. 2017. PMID: 28756878 Review.
-
Role of CXCR4 in the pathogenesis of acute myeloid leukemia.Theranostics. 2013;3(1):34-9. doi: 10.7150/thno.5150. Epub 2013 Jan 13. Theranostics. 2013. PMID: 23382784 Free PMC article. Review.
Cited by
-
3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.Cancer Cell Int. 2021 May 26;21(1):279. doi: 10.1186/s12935-021-01980-2. Cancer Cell Int. 2021. PMID: 34039348 Free PMC article.
-
Sirt1 gene confers Adriamycin resistance in DLBCL via activating the PCG-1α mitochondrial metabolic pathway.Aging (Albany NY). 2020 Jun 22;12(12):11364-11385. doi: 10.18632/aging.103174. Epub 2020 Jun 22. Aging (Albany NY). 2020. PMID: 32570218 Free PMC article.
-
Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment.Mol Cancer. 2019 Mar 30;18(1):69. doi: 10.1186/s12943-019-0992-4. Mol Cancer. 2019. PMID: 30927928 Free PMC article. Review.
-
Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.Cancer Biol Ther. 2018;19(9):825-834. doi: 10.1080/15384047.2018.1472188. Epub 2018 Jul 3. Cancer Biol Ther. 2018. PMID: 29969367 Free PMC article.
-
The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities.Curr Hematol Malig Rep. 2023 Apr;18(2):19-32. doi: 10.1007/s11899-023-00688-6. Epub 2023 Feb 13. Curr Hematol Malig Rep. 2023. PMID: 36780103 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials